Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00380302 · ClinicalTrials.gov registry record · Phase 1
Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.
A Phase 1 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 1
- Development phase
- 162
- Enrollment target
NCT00380302 is a Phase 1 study that has completed, run by Sanofi. The registered enrollment target is 162 participants.
The verdict
NCT00380302, a Phase 1 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 162 participants
- Enrollment target
Study Summary
Primary: This study is being conducted to evaluate if AVE1625 is safe and tolerated in patients with Alzheimer's disease that is not too severe. There is also evaluation of whether patients who take the study medication improve compared to patients who take a placebo (sugar pill). Secondary:The study will also evaluate the blood levels of the study medication, AVE1625 in patients who join the study.
Interventions
- DRUG AVE1625
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2006-09 |
| Est. Completion | 2007-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00380302
The ClinicalTrials.gov registry entry for NCT00380302 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AVE1625 is the first listed.
NCT00380302 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00380302 about?
NCT00380302 is a clinical study titled "Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.". Primary: This study is being conducted to evaluate if AVE1625 is safe and tolerated in patients with Alzheimer's disease that is not too severe. There is also evaluation of whether patients who take the study medication improve compared to patients who take a placebo (sugar pill). Secondary:The stu...
What is the current status of trial NCT00380302?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 162 participants. The study started on 2006-09. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00380302?
The interventions under investigation include: AVE1625 (DRUG).
Who is sponsoring clinical trial NCT00380302?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.